ArticleBMC immunology2026
Diagnostic and prognostic value of deregulated miR-6822-3p in patients with severe pneumonia.
Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPneumonia is a common cause of morbidity and mortality, with severe cases often progressing to complications such as sepsis and respiratory failure. Early diagnosis and intervention are crucial for improving outcomes. MicroRNAs (miRNAs) have been identified as potential biomarkers for various diseases, including pneumonia. This study aimed to evaluate the potential role of miR-6822-3p as a diagnostic and prognostic biomarker in severe pneumonia and to explore its underlying mechanisms.
methodsThe GSE153131 dataset from the GEO database was analyzed to identify differentially expressed miRNAs. Serum samples from 70 mild pneumonia patients, 70 severe pneumonia patients, and 70 healthy controls were used to validate miR-6822-3p expression. In vitro experiments using A549 and THP-1 cells were conducted to investigate the role of miR-6822-3p in inflammation and pyroptosis.
resultsmiR-6822-3p was significantly upregulated in severe pneumonia patients and showed potential as a diagnostic biomarker. In vitro studies revealed that miR-6822-3p promoted inflammation and pyroptosis. High miR-6822-3p expression was associated with poorer clinical outcomes, including lower 28-day survival rates.
conclusionsmiR-6822-3p may be a potential diagnostic and prognostic biomarker for severe pneumonia. Further studies are needed to validate its clinical utility and explore its therapeutic potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.